Marina Udier has been promoted to chief executive officer at Nouscom AG, having served in this role on an interim basis since May 2019. She is joined on the management team by Patricia Delaite, newly appointed as chief medical officer. Nouscom recently started human studies of its lead cancer vaccine which is based on neoantigens.
Dr Udier joined Nouscom as chief operating officer in 2016 from the venture capital group Versant Ventures. Prior to this, she held senior development and Commercial roles at Novartis. She earned a PhD in organic chemistry from Yale University, US.
Dr Delaite is a medical doctor who joins from AMAL Therapeutics, a cancer drug developer recently acquired by Boehringer Ingelheim GmbH.
Nouscom announced the appointment on 26 February 2020.
Copyright 2020 Evernow Publishing Ltd